IsoRay announces new applications of its Cesium-131 cancer treatment

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, recently announced the first Cesium-131 colon cancer treatment. The company has also provided Cesium-131 seeds to Canada for research initiatives into treatments for other cancers. In 2009 the company announced treatments of lung, head and neck cancers.

Read more in IsoRay press releases

IsoRay is a WTC client

This entry was posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s